Core Viewpoint - Soligenix, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $7.5 million to fund research, development, and general corporate purposes [3]. Group 1: Offering Details - The company is offering 5,555,560 shares of common stock and warrants to purchase an equal number of shares at a combined price of $1.35 per share and warrant [1]. - The existing warrants will be amended to have a reduced exercise price of $1.35 per share and will expire in line with the new warrants [2]. - The closing of the offering is expected around September 29, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research and development, commercialization activities, working capital, and general corporate purposes [3]. Group 3: Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs [7]. - The company is advancing HyBryte™ (SGX301) for the treatment of cutaneous T-cell lymphoma and has completed a second Phase 3 study [7]. - Other development programs include treatments for psoriasis, inflammatory diseases, and a ricin toxin vaccine candidate [8].

Company Overview - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs [3] - The company has a Specialized BioTherapeutics segment that is advancing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), towards potential commercialization following the successful completion of a second Phase 3 study [3] - Other development programs include SGX302 for psoriasis, SGX942 for inflammatory diseases, and SGX945 for Behçet's Disease [3] Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine candidate, and vaccines targeting filoviruses and COVID-19 [4] - The vaccine programs utilize the proprietary ThermoVax® technology and have received support from government grants and contracts from agencies such as NIAID, DTRA, and BARDA [4] Upcoming Events - Christopher J. Schaber, Ph.D., President and CEO of Soligenix, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with an on-demand presentation available on September 5, 2025 [1] - Key management members will hold one-on-one meetings throughout the conference, and registered attendees can schedule meetings via the conference platform [2]